# 23andMe

23andMe is an Asset Manager based in Sunnyvale, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** Sunnyvale, United States
- **Region:** North America
- **Address:** Sunnyvale, CA, United States
- **Assets under management:** Undisclosed
- **Website:** 23andme.com
- **LinkedIn:** https://www.linkedin.com/company/23andme

## Regulatory record

- **Reports private funds:** No

## About

23andMe is a personal genetics company that provides DNA testing services for ancestry composition and health predispositions. Its offerings include ancestry breakdowns across 4,500+ regions, health screening for 95+ conditions, and pharmacogenetics reports. The company also offers subscription-based premium services with ongoing genetic insights and a total health platform incorporating blood testing for longevity guidance.

## Sectors

- Digital Health
- Healthcare Services

## Offices

- Santa Clara, CA
- New York, NY
- Mountain View, CA
- Seattle, WA
- Austin, TX

## Questions

### Who runs investment decisions at 23andMe?

23andMe does not operate as an investment firm. The company's strategic direction is set by its board of directors, which as of 2025 has not publicly named a permanent CEO after Anne Wojcicki's removal in September 2024. Investment-related decisions, such as data licensing deals or capital allocation, are handled by the executive team under board oversight.

### How does 23andMe generate revenue beyond kit sales?

In addition to one-time kit purchases, 23andMe offers two subscription tiers — 23andMe+ Premium for ancestry and health reports ($69/year) and 23andMe+ Total Health ($199/year) that includes exome sequencing and blood testing. The firm also licenses aggregated, de-identified genetic data to pharmaceutical and research partners, which has been a key revenue stream for its drug discovery arm.

### What investment stages does 23andMe target?

23andMe is not an asset manager and does not target investment stages. The firm's business model is operational — selling genetic testing kits, subscription services, and data licenses — rather than deploying capital into external companies or funds.

### Does 23andMe participate in fund commitments or only direct deals?

23andMe does not participate in fund commitments or direct investment deals. The company's research collaborations with pharmaceutical firms (e.g., GSK) are structured as data-access partnerships, not equity investments.

### How does 23andMe protect customer data?

23andMe states on its website that it uses enhanced measures to keep customer data secure and offers privacy-by-design controls. Customers can choose whether to participate in research; data shared for research is de-identified and aggregated. The firm has not disclosed a specific data-breach incident affecting customer consent choices since its 2023 security breach (per company disclosures, 2023).

## Related profiles

- [BTG High Growth Opportunities Fund](https://altss.com/profile/btg-high-growth-opportunities-fund)
- [Global Lighting Technologies](https://altss.com/profile/global-lighting-technologies)

---

Last updated: 2026-07-10T18:51:47.000Z

Canonical page: https://altss.com/profile/23andme

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology